Last reviewed · How we verify
MOR103
At a glance
| Generic name | MOR103 |
|---|---|
| Sponsor | MorphoSys AG |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis (PHASE1, PHASE2)
- Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MOR103 CI brief — competitive landscape report
- MOR103 updates RSS · CI watch RSS
- MorphoSys AG portfolio CI